MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/1756-185x.14951

Медицинская библиотека · International journal of rheumatic diseases · 2023

The role of plateletcrit in Takayasu arteritis: A potential biomarker for disease activity and 6-month treatment response.

Sun Ying, Cui Xiaomeng, Kong Xiufang, Chen Huiyong, Wu Sifan, Ma Lili, Ding Zhenqi, Jiang Lindi

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

To determine the role of plateletcrit as a potential biomarker for disease activity and treatment response in Takayasu arteritis (TAK).

METHODS

Totally, 215 newly diagnosed TAK patients were consecutively enrolled. Demographic data, clinical manifestations, laboratory and imaging examinations, and treatment strategy were recorded at baseline and at each visit during the 6-month treatment period. Normal plateletcrit (0.1%-0.4%) and hyper-plateletcrit (>0.4%) observed at baseline were used as group criteria.

RESULTS

At baseline, the overall plateletcrit was 0.32 (0.24-0.38)%, with a normal and high level observed in 172 (80.00%) and 43 (20.00%) patients, respectively. Baseline plateletcrit was significantly higher in patients with active disease and associated with inflammatory biomarkers, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and interleukin (IL)-6 (all p < .01). At 6 months, complete remission was achieved in 171 (79.53%) patients, and a significant decrease in plateletcrit was observed in these cases (p < .01). Patients with a normal baseline plateletcrit were more likely to achieve complete remission compared to those with a high baseline plateletcrit (HR = 4.65, 95% CI: 2.38-19.08, p < .01). In addition, ESR (p = .01) and IL-6 (p = .02) levels were still higher in patients with a high baseline plateletcrit at 6 months. Progression of vascular lesions was indicated in 18 (8.37%) patients at 6 months, and these patients also had significantly higher baseline plateletcrit (p = .03).

CONCLUSION

Plateletcrit levels were positively related to disease activity and inflammatory index in TAK. Importantly, patients with high baseline plateletcrit levels may show a worse treatment response at 6 months.

Для цитирования: Sun Ying, Cui Xiaomeng, Kong Xiufang, Chen Huiyong, Wu Sifan, Ma Lili, Ding Zhenqi, Jiang Lindi. The role of plateletcrit in Takayasu arteritis: A potential biomarker for disease activity and 6-month treatment response.. International journal of rheumatic diseases. 2023. DOI: 10.1111/1756-185x.14951.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.